readthroughSign in
CompanyPRLDNasdaqWilmington, DE

Prelude Therapeutics Incorporated

Prelude Therapeutics develops precision oncology medicines, including KAT6A degraders and JAK2V617F mutant selective inhibitors, as well as degrader antibody conjugates for cancer treatment.

10-QNov 16Latest SEC filing
Nov 16Latest story